Over the past three decades, collaborative arrangements between academic biomedical researchers and private industry have grown dramatically, resulting in medical innovations that have benefited society greatly. However, a growing chorus of criticism directed at private companies that sponsor...

Public-private partnerships offer a promising alternative paradigm for pharmaceutical innovation in complex disease areas where there are both strong commercial interests and significant public need. They have the potential to reduce the tremendous waste associated with duplicative unsuccessful...